You can buy Rusodx at the lowest price in the online pharmacy Nextgen.ooo . Ruxolitinib is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2,3, which are tyrosine kinases involved in cytokine signaling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib blocks the abnormal cell signaling pathways and prevents abnormal blood cell proliferation. Due to the large number of patients with myeloproliferative neoplasms harboring JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. 
 
Ruxolitinib was first approved by the FDA for the treatment of adult patients with myelofibrosis in 2011, and then approved by the EMA in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults with an inadequate response to hydroxyurea or intolerance to hydroxyurea. And in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. Ruxolitinib in topical form is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin diseases.